University of Florida
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Florida sits in the top decile of US sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count).
University of Florida: 1,106 sponsored US clinical trials, 170 recruiting.
University of Florida sponsors 1,106 registered US clinical trials on ClinicalTrials.gov, 170 of them currently recruiting, and 754 completed. 103 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 17 trials.
Top-decile sponsor footprint
University of Florida ranks in the top decile of sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
754 of 855 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,106 total, page 13 of 23
Smartphone Technology: Young Adult Drinking
NCT02963818
Novel Coating to Minimize Bacterial Adhesions and Tooth Wear in Denture Acrylic
NCT02834832
A 14 Week Study of Mindfulness Effects on Attentional Control in Older Adults
NCT02714426
Point-of-Care Adipose-derived Cells for Hair Growth
NCT02729415
Screening in Oculopharyngeal Muscular Dystrophy
NCT02877784
Genioglossus Muscle Training for Snoring and Obstructive Sleep Apnea
NCT02834767
RADTOX: Measuring Radiation Toxicity Using Circulating DNA
NCT02941029
Continuous Blockade of the Brachial Plexus
NCT02769429
Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
NCT02855580
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
NCT02465268
Effect of D-allulose in Addition to Oral Sucrose Load
NCT02714413
Effects of Botulinum Toxin on Muscle and Brain Activity
NCT02837185
PEAKS: Validation of Mobile Technologies
NCT02888483
Pediatric Type 1 Diabetes and Retinopathy
NCT02691312
Identification of Clinically Relevant Markers of Deep Brain Stimulation Electrode Impedance
NCT02794233
Microfluidics and Transcriptomics in Post Solid Organ Transplant Patients
NCT02776111
Young Adult Naturalistic Alcohol Study (YANAS) Using Smartphone Technology in a Simulated Laboratory Environment
NCT02841735
OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)
NCT02814552
Impact of Oral Carbohydrate Consumption Prior to Cesarean Section
NCT02684513
Efficacy of Pea Hull Fibre Supplementation
NCT02778230
Resveratrol and Exercise to Treat Functional Limitations in Late Life
NCT02523274
Mindfulness With Biofeedback
NCT02769403
Influence of Monopoly Game on Subtle Behaviors
NCT02729389
Study of Oral Treatments for Hepatitis C
NCT02786537
Evaluation of Diagnostic Yield of EUS-Guided Tissue Sampling
NCT02979509
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
NCT02370888
Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy
NCT02724319
Oral Metagenomic Biomarkers in Rheumatoid Arthritis
NCT02544334
Breast Cancer Lung Late Effects
NCT02725840
Tongue Motor Recruitment During Exercise
NCT02687737
Resistant Maltodextrin Supplementation: Gastrointestinal Health
NCT02733263
SMOFlipid to Lessen the Severity of Neonatal Cholestasis
NCT02721277
The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study
NCT02676466
Aneurysmal Subarachnoid Hemorrhage and Superior Mesenteric Artery Flow Study
NCT02684500
The Feasibility of the PAINReportIt Guided Relaxation Intervention-INPATIENT
NCT02729350
Imaging the Patterns of Breast Cancer Early Metastases
NCT02706964
Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults
NCT02632487
Behavioral Expressions in Alzheimer's Disease
NCT02719834
The Feasibility of the PAINReportIt Guided Relaxation Intervention-Outpatient
NCT02729363
Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)
NCT02710162
Microbiome and the Gut-Brain Axis
NCT02693327
Apathy in Tourette Syndrome and Changes in Quality of Life
NCT02765178
Precision Medicine Guided Treatment for Cancer Pain
NCT02664350
Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)
NCT02710110
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus
NCT02548650
The Motor Network in Essential Tremor: Mechanisms of Therapy
NCT02712515
Study 3: Minocycline Decreases Microglia Activation
NCT02213575
A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers
NCT02690285
Functional and Structural Imaging and Motor Control in Spinocerebellar Ataxia
NCT02488031
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
NCT02669966
What is open in the University of Florida pipeline
170 recruiting of 1,106 indexed (15% open); 754 completed (68%).
Phase mix: 103 late (III/IV) vs 232 early (I/II) (early-phase heavy).
Top condition: Coronary Artery Disease (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Florida: open-pipeline peers nationwide
Peers matched on 1,106 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,106 trials (± recruiting share)
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
- Candel Therapeutics · 15% recruiting · 13 trials
Related
What to do with this University of Florida page
1,106 registered trials is a research-attention snapshot, not an endorsement of University of Florida or any single study.
- 170 of University of Florida's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary Artery Disease is the condition University of Florida studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Florida pipeline card: 1,106 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.